Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: The key role of metformin at the start and after more than one year of therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 1, 2005, Pages 39-43

  Ibáñez, Lourdes ^a   De Zegher, Francis ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; DROSPIRENONE PLUS ETHINYLESTRADIOL; FLUTAMIDE; GLUCOSE; INSULIN; INTERLEUKIN 6; LIPID; METFORMIN;

ADOLESCENT; ADULT; ARTICLE; ATHEROGENESIS; BODY COMPOSITION; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPOLYSIS; MAJOR CLINICAL STUDY; OBESITY; OVARY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANDROSTENES; ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; ETHINYL ESTRADIOL; FEMALE; FLUTAMIDE; HUMANS; HYPERANDROGENISM; LIPOLYSIS; METFORMIN; POLYCYSTIC OVARY SYNDROME; TIME FACTORS;

EID: 12244285665     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1405     Document Type: Article

References (35)

1. Dunaif A, Thomas A 2000 Current concepts in the polycystic ovary syndrome. Annu Rev Med 52:401-419
2. Baumann EE, Rosenfield RL 2002 Polycystic ovary syndrome in adolescence. The Endocrinologist 12:333-348
3. Asunción M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale H 2000 A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434-2438
4. Kirchengast S, Huber J 2001 Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 16:1255-1260
5. Ibáñez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F 2003 Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in non-obese adolescents and young women with ovarian hyperandrogenism. J Clin Endocrinol Metab 88:2600-2606
6. Ibáñez L, de Zegher F 2003 Flutamide-metformin to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 88:4720-4724
7. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS 2003 Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:4649-4654
8. Ibáñez L, de Zegher F 2004 Ethinylestradiol-drospirenone, flutamide-met-formin, or both for adolescents and young women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 89:1592-1597
9. Ibáñez L, Valls C, Cabré S, de Zegher F 2004 Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. J Clin Endocrinol Metab 89:4716-4720
10. Ibáñez L, de Zegher F 2004 Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third-to fourth-generation OC reduces body adiposity. Hum Reprod 19:1725-1727
11. Ibáñez L, Valls C, Ferrer A, Ong K, Dunger D, de Zegher F 2002 Additive effects of insulin-sensitizing and antiandrogen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia and anovulation. J Clin Endocrinol Metab 87:2870-2874
12. Nestler JE 2002 Should patients with polycystic ovary syndrome be treated with metformin? An enthusiastic endorsement. Hum Reprod 17:1950-1953
13. de Leo V, La Marca A, Petraglia F 2003 Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24:633-667
14. Costello MF, Eden JA 2003 A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 79:1-13
15. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE 2003 Controversies in endocrinology. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 88:1927-1932
16. Homburg R, Lambalk CB 2004 Debate: polycystic ovary syndrome in adolescence - a therapeutic conundrum. Hum Reprod 19:1-4
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 1997 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197
18. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, Dupont B, Stoner E, Levy DJ, Pang S, Levine LS 1983 Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 56:320-325
19. Sakkal-Alkaddour H, Zhang L, Yang X, Chang YT, Kappy M, Slover RS 1996 Studies of 3β-hydroxysteroid dehydrogenase genes in infants and children manifesting premature pubarche and increased adrenocorticotropin-stimulated Δ5-steroid levels. J Clin Endocrinol Metab 81:3961-3965
20. Ibáñez L, Ong K, de Zegher F, Marcos MV, del Rio L, Dunger D 2003 Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinemia and androgenemia from pre-puberty to post-menarche. Clin Endocrinol (Oxf) 58:372-379
21. Taylor RW, Keil D, Gold EJ, Williams SM, Goulding A 1998 Body mass index, waist girth, and waist-to-hip ratio as indexes of total and regional adiposity in women: evaluation using receiver operating characteristic curves. Am J Clin Nutr 67:44-49
22. Kiebzak GM, Leamy LJ, Pierson LM, Nord RH, Zhang ZY 2000 Measurement precision of body composition variables using the Lunar DPX-L densitometer. J Clin Densitom 3:35-41
23. Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM 2003 Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 13:674-682
24. Ferreira I, Twisk JW, van Mechelen W, Kemper HC, Seidell JC, Stehouwer CD 2004 Current and adolescent body fatness and fat distribution: relationships with carotid intima-media thickness and large artery stiffness at the age of 36 years. J Hypertens 22:145-155
25. Ferreira I, Snijder MB, Twisk JWR, van Mechelen W, Kemper HCG, Seidell JC, Stehouwer CDA 2004 Central fat mass versus peripheral fat and lean mass: opposite (adverse versus favorable) associations with arterial stiffness?. The Amsterdam Growth and Health Longitudinal Study. J Clin Endocrinol Metab 89:2632-2639
26. Goldstein BJ, Scalia R 2004 Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89:2563-2568
27. Pittas AG, Joseph NA, Greenberg AS 2004 Hot topic: adipocytokynes and insulin resistance. J Clin Endocrinol Metab 89:447-452
28. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy II PF, Fitzpatrick LA 2003 Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:2562-2568
29. Elting MW, Korsen TJM, Bezemer PD, Schoemaker J 2001 Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 16:556-560
30. Lakhani K, Seifalian AM, Hardiman P 2002 Impaired carotid viscoelastic properties in women with polycystic ovaries. Circulation 106:81-85
31. Ibáñez L, Valls C, Potau N, Marcos MV, de Zegher F 2000 Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 85:3526-3530
32. Nestler JE, Jakubowicz DJ 1997 Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metab 82:4075-4079
33. Morin-Papunen L, Vaukhonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS 2003 Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 88:148-156
34. Ibáñez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F 2004 Insulin sensitization early post-menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 144:23-29
35. Ibáñez L, Valls C, Marcos MV, Ong K, Dunger D, de Zegher F 2004 Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and posrpubertal discontinuation of metformin. J Clin Endocrinol Metab 89:4331-4337